Unlocking the Secrets of GI Diseases: Inotiv’s Drug Discovery Program

Welcome to the forefront of gastrointestinal (GI) disease research with Inotiv’s drug discovery and development program, where science meets innovation to redefine the “contract to discover partnership” with gastrointestinal researchers and developers. With a multidisciplinary approach blending advanced disease modeling and innovative methodologies, we are committed to unraveling the intricacies of gastrointestinal disorders and advancing novel therapeutic solutions. At the heart of our research program lies a relentless pursuit of understanding the underlying mechanisms driving gastrointestinal diseases, including IBD. By integrating molecular and cell sciences, molecular pathology, and proteogenomic capabilities, Inotiv scientists provide key insights into the mechanism of therapeutic intervention, the safety of novel therapies, and the predicted clinical success of our client’s drug programs.